SONNET BIOTHERAPEUTICS HOLDINGS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.84 USD | -0.54% |
|
+8.24% | +5.75% |
| Mar. 11 | Traders Anticipate Inflation Report as US Equities Open Lower on Wall Street | MT |
| Mar. 11 | Top Premarket Gainers | MT |
Valuation
| Fiscal Period: Settembre | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Capitalization 1 | 35.06 | 35.24 | 7.174 | 5.015 | 5.648 | - | - |
| Enterprise Value (EV) 1 | 35.06 | 35.24 | 7.174 | 5.015 | 5.648 | 5.648 | 5.648 |
| P/E ratio | - | -0.59 x | -0.21 x | -0.16 x | -0.85 x | -0.73 x | - |
| Yield | - | - | - | - | - | - | - |
| Capitalization / Revenue | - | 72.9 x | 20.5 x | 33.9 x | 34 x | - | - |
| EV / Revenue | - | 72.9 x | 20.5 x | 33.9 x | 34 x | - | - |
| EV / EBITDA | - | - | - | - | -0.38 x | - | - |
| EV / FCF | - | -1.56 x | - | - | -0.37 x | -0.27 x | -0.2 x |
| FCF Yield | - | -64% | - | - | -271% | -374% | -498% |
| Price to Book | - | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 44.3 | 189 | 222 | 1,750 | 3,070 | - | - |
| Reference price 2 | 791.6 | 186.6 | 32.34 | 2.865 | 1.840 | 1.840 | 1.840 |
| Announcement Date | 12/17/20 | 12/17/21 | 12/15/22 | 12/14/23 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: September | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | - | 0.4836 | 0.3499 | 0.1478 | 0.166 | - | - |
| EBITDA 1 | - | - | - | - | -15 | - | - |
| EBIT 1 | - | -25.09 | - | -18.79 | -14.15 | -17.48 | -28 |
| Operating Margin | - | -5,187.32% | - | -12,714.04% | -8,525.9% | - | - |
| Earnings before Tax (EBT) 1 | - | -24.98 | - | -18.83 | -12.99 | -13.94 | - |
| Net income 1 | - | -24.98 | - | -18.83 | -12.99 | -19.28 | -28 |
| Net margin | - | -5,165.92% | - | -12,741.15% | -7,824.7% | - | - |
| EPS 2 | - | -314.2 | -150.5 | -18.14 | -2.170 | -2.520 | - |
| Free Cash Flow 1 | - | -22.56 | - | - | -15.3 | -21.1 | -28.1 |
| FCF margin | - | -4,663.87% | - | - | -9,216.87% | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - |
| Announcement Date | 12/17/20 | 12/17/21 | 12/15/22 | 12/14/23 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: September | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 0.1298 | 0.0953 | 0.0621 | 0.0628 | 0.0373 | 0.0364 | 0.0368 | 0.0373 | 0.0186 | - | 0.057 | 0.056 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -6.215 | -8.21 | -7.867 | - | - | - | - | -3.6 | -1.279 | -3.869 | -3.879 | -3.979 |
| Operating Margin | -4,788.1% | -8,613.32% | -12,674.77% | - | - | - | - | -9,662.24% | -6,864.57% | - | -6,805.26% | -7,105.36% |
| Earnings before Tax (EBT) 1 | -6.201 | -8.208 | -7.877 | - | - | - | - | -3.677 | -1.169 | 0.3654 | -3.879 | -3.979 |
| Net income 1 | -6.201 | -8.208 | -7.877 | - | - | - | - | -3.677 | -1.169 | 0.3654 | -3.879 | -3.979 |
| Net margin | -4,777.33% | -8,611.52% | -12,690.54% | - | - | - | - | -9,867.79% | -6,272.2% | - | -6,805.26% | -7,105.36% |
| EPS 2 | -30.80 | -43.12 | -40.04 | -37.18 | -17.60 | -7.480 | -2.860 | -17.28 | -0.3100 | 0.0700 | -0.8433 | -0.6400 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 2/8/22 | 5/10/22 | 8/15/22 | 12/15/22 | 2/13/23 | 5/10/23 | 8/14/23 | 12/14/23 | 2/14/24 | 5/14/24 | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: September | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
| Free Cash Flow 1 | - | -22.6 | - | - | -15.3 | -21.1 | -28.1 |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - | - |
| Capex 1 | - | - | - | - | 0.2 | 0.2 | 0.2 |
| Capex / Sales | - | - | - | - | 120.48% | - | - |
| Announcement Date | 12/17/20 | 12/17/21 | 12/15/22 | 12/14/23 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
1.84
USD
Average target price
11.5
USD
Spread / Average Target
+525.00%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +5.75% | 5.65M | |
| +32.09% | 693B | |
| +29.39% | 584B | |
| -1.34% | 372B | |
| +20.34% | 332B | |
| +7.39% | 294B | |
| +14.25% | 239B | |
| -3.03% | 211B | |
| +10.02% | 210B | |
| +8.49% | 168B |
- Stock Market
- Equities
- SONN Stock
- Financials Sonnet BioTherapeutics Holdings, Inc.